Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 21

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 21
---
 Inc., a Delaware corporation and a wholly-owned subsidiary of MIRA (“Merger Sub”), and SKNY. Merger Sub will merge with and into SKNY, with Merger Sub being the surviving corporation (the “Merger”). Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein upon the consummation of the transactions contemplated by the Merger Agreement, Merger Sub will merge with and into SKNY, with SKNY continuing as the surviving corporation and a wholly-owned subsidiary of MIRA. As a result of the Merger, all of the issued and outstanding shares of common stock of SKNY, $0.0001 par value per share (“SKNY Common Stock”) immediately prior to the Effective Time shall no longer be outstanding and shall be exchanged for and automatically converted into the number of fully paid and nonassessable shares of MIRA Common Stock as calculated in accordance with the terms of the Merger Agreement. The Exchange Ratio is estimated to result in SKNY shareholders holding 50% of the issued and outstanding shares of MIRA Common Stock. Reasons for the Merger (see page 25) The MIRA Board considered various reasons for the Merger, as described later in this proxy statement under the section titled “ The Merger—Background of the Merger.” Fairness Opinion and Valuation Reports of Moore Financial Consulting (page 27) In March 14, 2025, MIRA retained Moore, as a financial advisor in connection with the Merger to conduct a valuation of MIRA and SKNY, and determination of the fairness of the Merger. In arriving at its opinion, Moore, among other things: (i) reviewed certain publicly available business and financial information concerning MIRA and SKNY and the industries in which they operate; (ii) analyzed MIRA’s share pricing as traded on the Nasdaq; (iii) reviewed certain internal financial analyses and forecasts prepared by MIRA’s and SKNY’s finance departments, delivered to Moore through written materials including Excel sheets, and orally, in several meetings and discussions throughout the valuation process; and (iv) performed such other financial studies and analyses and considered such other information as Moore deemed appropriate for the purposes of its opinion. The forecasts were provided to Moore in March 2025. These forecasts were predicted and based on projections through comparisons to a peer group consisting of publicly-listed pharmaceutical companies similar to SKNY’s area of focus. The peer group consisted of the following entities, which are all in the pharmaceutical industry: Eli Lib